Form 4: Agios Pharmaceuticals Executive Sarah Gheuens Reports Stock Transactions
SEC Form 4 Filing
Chief Medical Officer Sarah Gheuens reports acquisition and disposal of Agios Pharmaceuticals stock related to vesting of restricted stock units.
Summary
- On July 1, 2024, Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, acquired 8,375 shares of common stock upon vesting of restricted stock units.
- Simultaneously, Gheuens disposed of 3,705 shares at a price of $43.85 to cover tax withholding obligations related to the vesting.
- Following these transactions, Gheuens directly owns 43,736 shares of Agios Pharmaceuticals common stock and 16,749 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation and tax obligations.
Positives
- The vesting of restricted stock units indicates a continued alignment of the executive's interests with the company's performance.
Future Outlook
The restricted stock units will vest in three equal annual installments beginning on July 1, 2024.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their holdings in the company's stock.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 07/01/2023 | Date of the reporting person's restricted stock unit agreement. |
| 07/01/2024 | Date of the reported transactions: acquisition of shares from restricted stock units and sale of shares for tax withholding. |
| 07/01/2024 | Beginning on this date, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 07/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.